Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), also known as platelet-activating factor acetylhydrolase (PAF-AH), is a unique member of the phospholipase A(2) superfamily. This enzyme is characterized by its ability to specifically hydrolyze PAF as well as glycerophospholipids containing short, truncated, and/or oxidized fatty acyl groups at the sn-2 position of the glycerol backbone. In humans, Lp-PLA(2) circulates in active form as a complex with low- and high-density lipoproteins. Clinical studies have reported that plasma Lp-PLA(2) activity and mass are strongly associated with atherogenic lipids and vascular risk. These observations led to the hypothesis that Lp-PLA(2) activity and/or mass levels could be used as biomarkers of cardiovascular disease and that inhibition of the activity could offer an attractive therapeutic strategy. Darapladib, a compound that inhibits Lp-PLA(2) activity, is anti-atherogenic in mice and other animals, and it decreases atherosclerotic plaque expansion in humans. However, disagreement continues to exist regarding the validity of Lp-PLA(2) as an independent marker of atherosclerosis and a scientifically justified target for intervention. Circulating Lp-PLA(2) mass and activity are associated with vascular risk, but the strength of the association is reduced after adjustment for basal concentrations of the lipoprotein carriers with which the enzyme associates. Genetic studies in humans harboring an inactivating mutation at this locus indicate that loss of Lp-PLA(2) function is a risk factor for inflammatory and vascular conditions in Japanese cohorts. Consistently, overexpression of Lp-PLA(2) has anti-inflammatory and anti-atherogenic properties in animal models. This thematic review critically discusses results from laboratory and animal studies, analyzes genetic evidence, reviews clinical work demonstrating associations between Lp-PLA(2) and vascular disease, and summarizes results from animal and human clinical trials in which administration of darapladib was tested as a strategy for the management of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Zelko, I. N., Mariani, T. J., & Folz, R. J. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00905-x · Cited by 2,212
Distinct macrophage phenotypes contribute to kidney injury and repair
Lee, S., Huen, S., Nishio, H., Nishio, S., Lee, H. K., Choi, B.-S., Ruhrberg, C., & Cantley, L. G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060615 · Cited by 906 · cited 1×
“The properties of macrophages in atherosclerotic lesions can vary dramatically between two extremes: proinflammatory M1 macrophages and anti-inflammatory M2 macrophages; these cells can switch from one phenotype to the other depending on micro-environmental cues such as differentiation factors produced in the lesion a…”
Kadl, A., Meher, A. K., Sharma, P. R., Lee, M. Y., Doran, A. C., Johnstone, S. R., Elliott, M. R., Gruber, F., Han, J., Chen, W., et al. (2010) · Circulation Research · doi:10.1161/circresaha.109.215715 · Cited by 573 · cited 1×
“In addition to M1 and M2, other macrophage phenotypes have been described, including sub-species generated in response to stimulation with oxidized phospholipids [OxPL, (50)].”
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis
Vadas, P., Gold, M., Perelman, B., Liss, G. M., Lack, G., Blyth, T., Simons, F. E. R., Simons, K. J., Cass, D., & Yeung, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070030 · Cited by 526
Atherosclerosis and oxidative stress.
(2008) · PubMed · doi:10.14670/hh-23.381 · Cited by 254
Garza, C. A., Montori, V. M., McConnell, J. P., Somers, V. K., Kullo, I. J., & Lopez-Jimenez, F. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60992-0 · Cited by 159
Cited by
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke
Esenwa, C. C., & Elkind, M. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.125 · Cited by 281
Reis, J. F., Monteiro, V. V. S., de Souza Gomes, R., do Carmo, M. M., da Costa, G. V., Ribera, P. C., & Monteiro, M. C. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1076-5 · Cited by 256
Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA 2 Inhibitor
Measom, N. D., Down, K. D., Hirst, D. J., Jamieson, C., Manas, E. S., Patel, V. K., & Somers, D. O. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00281 · Cited by 253
Acharya, N. K., Levin, E. C., Clifford, P. M., Han, M., Tourtellotte, R., Chamberlain, D., Pollaro, M., Coretti, N. J., Kosciuk, M. C., Nagele, E. P., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122254 · Cited by 121
Chapman, M. J., Orsoni, A., Tan, R., Mellett, N. A., Nguyen, A., Robillard, P., Giral, P., Thérond, P., & Meikle, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p119000543 · Cited by 65
“by sdLDL, the effect of statin treatment on its mass and activity were determined (23, 24).”
BackgroundSmesny, S., Milleit, B., Schaefer, M. R., Hipler, U.-C., Milleit, C., Wiegand, C., Hesse, J., Klier, C. M., Holub, M., Holzer, I., et al. (2015) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.07.001 · Cited by 36
Wang, Y.-J., Chang, S.-B., Wang, C.-Y., Huang, H.-T., & Tzeng, S.-F. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115133 · Cited by 12
Metadata
- Authors
- Rosenson, R. S., & Stafforini, D. M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 53
- Issue
- 9
- Pages
- 1767-1782
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2032972268
- Cited by
- 165
- References
- 7
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.